- Conditions
- Dry Eye Disease
- Interventions
- 0.003% AR-15512 ophthalmic solution, Artificial tears
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Ocular Redness
- Interventions
- Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 6
- States / cities
- Colorado Springs, Colorado • Louisville, Kentucky • Andover, Massachusetts + 3 more
- Conditions
- Dry Eye Syndromes
- Interventions
- Eye Drops with Experimental Preservative
- Other
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- 0.003% AR-15512 ophthalmic solution, Artificial Tears
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
- Conditions
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
- Interventions
- QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution
- Drug
- Lead sponsor
- Qlaris Bio, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ocular Hyperemia
- Interventions
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye Syndromes
- Interventions
- Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida